Guide to anticoagulant therapy. Part 1: Heparin. American Heart Association.

[1]  D. Massel,et al.  Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. , 1990, The Journal of clinical investigation.

[2]  O. Guilbaud,et al.  Low molecular weight heparin given the evening before surgery compared with conventional low‐dose heparin in prevention of thrombosis , 1988, The British journal of surgery.

[3]  J. Lerat,et al.  Randomized trial of a low-molecular-weight heparin (Kabi 2165) versus adjusted-dose subcutaneous standard heparin in the prophylaxis of deep-vein thrombosis after elective hip surgery. , 1989, Haemostasis.

[4]  J. Hirsh,et al.  Unfractionated heparin inhibits thrombin-catalysed amplification reactions of coagulation more efficiently than those catalysed by factor Xa. , 1989, The Biochemical journal.

[5]  V. Kakkar,et al.  Efficacy and safety of low‐molecular‐weight heparin (CY216) in preventing postoperative venous thrombo‐embolism: A co‐operative study , 1985, The British journal of surgery.

[6]  M. Blajchman,et al.  Effects of Unfractionated Heparin, Dermatan Sulfate and Low Molecular Weight Heparin on Vessel Wall Permeability in Rabbits a , 1989, Annals of the New York Academy of Sciences.

[7]  J. Hsia,et al.  Heparin-induced prolongation of partial thromboplastin time after thrombolysis: relation to coronary artery patency. HART Investigators. , 1992, Journal of the American College of Cardiology.

[8]  H. Baumgartner,et al.  The role of blood flow in platelet adhesion, fibrin deposition, and formation of mural thrombi. , 1973, Microvascular research.

[9]  J. Caen.  A Randomized Double-Blind Study Between a Low Molecular Weight Heparin Kabi 2165 and Standard Heparin in the Prevention of Deep Vein Thrombosis in General Surgery , 1988, Thrombosis and Haemostasis.

[10]  P. Prandoni,et al.  A Randomised Trial of Subcutaneous Low Molecular Weight Heparin (CY 216) Compared with lntravenous Unfractionated Heparin in the Treatment of Deep Vein Thrombosis , 1991, Thrombosis and Haemostasis.

[11]  T. Bjornsson,et al.  Heparin kinetics determined by three assay methods , 1982, Clinical pharmacology and therapeutics.

[12]  J. Badimón,et al.  Mechanisms of arterial thrombosis in nonparallel streamlines: platelet thrombi grow on the apex of stenotic severely injured vessel wall. Experimental study in the pig model. , 1989, The Journal of clinical investigation.

[13]  D. Meuleman,et al.  Time courses of the antithrombotic effects, bleeding enhancing effects and interactions with factors Xa and thrombin after administration of low molecular weight heparinoid Org 10172 or heparin to rats. , 1987, Thrombosis research.

[14]  C. D. de Swart,et al.  Kinetics of intravenously administered heparin in normal humans. , 1982, Blood.

[15]  G. Raskob,et al.  Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. , 1990, The New England journal of medicine.

[16]  H. Vinazzer,et al.  Prophylaxis of thromboembolism in general surgery: comparison between standard heparin and Fragmin. , 1990, Thrombosis research.

[17]  M. Samama,et al.  Low molecular weight heparin compared with unfractionated heparin in prevention of postoperative thrombosis , 1988, The British journal of surgery.

[18]  D. Pepper,et al.  Catabolism of low-dose heparin in man. , 1979, Thrombosis research.

[19]  R. Abbate,et al.  Effect of heparin, aspirin, or alteplase in reduction of myocardial ischaemia in refractory unstable angina , 1990, The Lancet.

[20]  E F Cook,et al.  Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy. , 1987, The American journal of medicine.

[21]  H. Rowsell,et al.  Resolution and organization of platelet-rich mural thrombi in carotid arteries of swine. , 1967, The American journal of pathology.

[22]  J. Hirsh,et al.  A randomized controlled trial of a low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery. , 1986, The New England journal of medicine.

[23]  E. A. Johnson,et al.  Molecular weight dependency of the heparin potentiated inhibition of thrombin and activated factor X. Effect of heparin neutralization in plasma. , 1979, Thrombosis research.

[24]  G. V. R. Born,et al.  INFLUENCE OF PLAQUE CONFIGURATION AND STRESS DISTRIBUTION ON FISSURING OF CORONARY ATHEROSCLEROTIC PLAQUES , 1989, The Lancet.

[25]  D. Waters,et al.  Reactivation of unstable angina after the discontinuation of heparin. , 1992, The New England journal of medicine.

[26]  W. T. Morgan,et al.  Histidine-rich glycoprotein modulation of the anticoagulant activity of heparin. Evidence for a mechanism involving competition with both antithrombin and thrombin for heparin binding. , 1987, The Journal of biological chemistry.

[27]  J. Walenga,et al.  Biochemical and Pharmacologic Studies on the Protamine Interactions with Heparin, Its Fractions and Fragments , 1985, Seminars in thrombosis and hemostasis.

[28]  M. Prins,et al.  Heparin Binding to Plasma Proteins, an Important Mechanism for Heparin Resistance , 1992, Thrombosis and Haemostasis.

[29]  D. Sackett,et al.  Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial. , 1985, The New England journal of medicine.

[30]  E. Falk.  Morphologic features of unstable atherothrombotic plaques underlying acute coronary syndromes. , 1989, The American journal of cardiology.

[31]  M. Pini,et al.  Subcutaneous vs Intravenous Heparin in the Treatment of Deep Venous Thrombosis – A Randomized Clinical Trial , 1990, Thrombosis and Haemostasis.

[32]  P. Leyvraz,et al.  Adjusted versus fixed-dose subcutaneous heparin in the prevention of deep-vein thrombosis after total hip replacement. , 1983, The New England journal of medicine.

[33]  P. Ostergaard,et al.  Neutralization of a Low Molecular Weight Heparin (LHN-1) and Conventional Heparin by Protamine Sulfate in Rats , 1986, Thrombosis and Haemostasis.

[34]  R. Collins,et al.  HEPARIN IN THE PRESENCE OR ABSENCE OF ANTIPLATELET THERAPY - AN OVERVIEW OF RANDOMIZED TRIALS IN ACUTE MYOCARDIAL-INFARCTION , 1992 .

[35]  D. Beeler,et al.  Multiple functional domains of the heparin molecule. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[36]  G. Simonneau,et al.  Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis. , 1993, Archives of internal medicine.

[37]  G. Houin,et al.  Unfractionated Heparin and CY 216: Pharmacokinetics and Bioavailabilities of the Antifactor Xa and IIa Effects after lntravenous and Subcutaneous Injection in the Rabbit , 1989, Thrombosis and Haemostasis.

[38]  R. Bar-Shavit,et al.  Binding of thrombin to subendothelial extracellular matrix. Protection and expression of functional properties. , 1989, The Journal of clinical investigation.

[39]  D. Hosmer,et al.  A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. , 1991, Archives of internal medicine.

[40]  M Gent,et al.  Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. , 1979, The New England journal of medicine.

[41]  A. Encke,et al.  Comparison of a low molecular weight heparin and unfractionated heparin for the prevention of deep vein thrombosis in patients undergoing abdominal surgery , 1988, The British journal of surgery.

[42]  J. Hirsh,et al.  A standard heparin nomogram for the management of heparin therapy. , 1991, Archives of internal medicine.

[43]  G. Bratt,et al.  Low molecular weight heparin (KABI 2165, Fragmin): pharmacokinetics after intravenous and subcutaneous administration in human volunteers. , 1986, Thrombosis research.

[44]  M. Karnovsky,et al.  Inhibition of vascular smooth muscle cell growth by endothelial cell-derived heparin. Possible role of a platelet endoglycosidase. , 1982, The Journal of biological chemistry.

[45]  B. Boneu,et al.  Disappearance of circulating anti-Xa activity after intravenous injection of standard heparin and of a low molecular weight heparin (CY 216) in normal and nephrectomized rabbits. , 1985, Thrombosis research.

[46]  K. Kurachi,et al.  The molecular-weight dependence of the rate-enhancing effect of heparin on the inhibition of thrombin, factor Xa, factor IXa, factor XIa, factor XIIa and kallikrein by antithrombin. , 1981, The Biochemical journal.

[47]  B. Eriksson,et al.  Prevention of deep-vein thrombosis and pulmonary embolism after total hip replacement. Comparison of low-molecular-weight heparin and unfractionated heparin. , 1991, The Journal of bone and joint surgery. American volume.

[48]  K.,et al.  Prevention of Deep Vein Thrombosis following Total Hip Replacement by Low Molecular Weight Heparinoid , 1992, Thrombosis and Haemostasis.

[49]  D. Atha,et al.  Contribution of 3-O- and 6-O-sulfated glucosamine residues in the heparin-induced conformational change in antithrombin III. , 1987, Biochemistry.

[50]  D. Doyle,et al.  Adjusted subcutaneous heparin or continuous intravenous heparin in patients with acute deep vein thrombosis. A randomized trial. , 1987, Annals of internal medicine.

[51]  Joan S. Reisch,et al.  Prevention of Venous Thromboembolism in General Surgical Patients: Results of Meta‐analysis , 1988, Annals of surgery.

[52]  J. Harenberg.  Pharmacology of low molecular weight heparins. , 1990, Seminars in thrombosis and hemostasis.

[53]  A. Wycherley,et al.  SAFETY AND EFFICACY OF WARFARIN STARTED EARLY AFTER SUBMASSIVE VENOUS THROMBOSIS OR PULMONARY EMBOLISM , 1986, The Lancet.

[54]  A. Walker,et al.  Predictors of bleeding during heparin therapy. , 1980, JAMA.

[55]  H. Büller,et al.  Prevention of deep vein thrombosis after hip replacement: randomised comparison between unfractionated heparin and low molecular weight heparin. , 1991, BMJ.

[56]  M. Petitou,et al.  Binding and endocytosis of heparin by human endothelial cells in culture. , 1985, Biochimica et biophysica acta.

[57]  D. Lane,et al.  Neutralization of heparin-related saccharides by histidine-rich glycoprotein and platelet factor 4. , 1986, The Journal of biological chemistry.

[58]  P. Leyvraz,et al.  Thromboembolic prophylaxis in total hip replacement: A comparison between the low molecular weight heparinoid Lomoparan and heparindihydroergotamine , 1992, The British journal of surgery.

[59]  G. Bratt,et al.  Two Daily Subcutaneous Injections of Fragmin as Compared with Intravenous Standard Heparin in the Treatment of Deep Venous Thrombosis (DVT) , 1990, Thrombosis and Haemostasis.

[60]  J. Hirsh,et al.  Discordance between the anti-Xa activity and the antithrombotic activity in an ultra-low molecular weight heparin fraction. , 1982, Thrombosis research.

[61]  G. Gensini,et al.  EFFECTIVENESS OF LOW-DOSE HEPARIN IN PREVENTION OF MYOCARDIAL REINFARCTION , 1987, The Lancet.

[62]  B. Lindblad,et al.  A 30‐year survey of pulmonary embolism verified at autopsy: An analysis of 1274 surgical patients , 1985, The British journal of surgery.

[63]  R. Rosenberg,et al.  The separation of active and inactive forms of heparin. , 1976, Biochemical and biophysical research communications.

[64]  B. Chong,et al.  Heparin-induced thrombocytopenia: studies with a new low molecular weight heparinoid, Org 10172 , 1989 .

[65]  K. Nordling,et al.  Extension and structural variability of the antithrombin-binding sequence in heparin. , 1984, The Journal of biological chemistry.

[66]  J. Gram,et al.  Does protamine chloride neutralize low molecular weight heparin sufficiently? , 1988, Thrombosis research.

[67]  L. Tavazzi,et al.  Randomised controlled trial of subcutaneous calcium-heparin in acute myocardial infarction , 1989 .

[68]  J. Wilson,et al.  Heparin therapy: a randomized prospective study. , 1979, American heart journal.

[69]  P. Théroux,et al.  Aspirin, heparin, or both to treat acute unstable angina. , 1988, The New England journal of medicine.

[70]  J. Hirsh,et al.  Neutralization of Enoxaparine-lnduced Bleeding by Protamine Sulfate , 1990, Thrombosis and Haemostasis.

[71]  T. Barrowcliffe,et al.  Anticoagulant properties of heparin fractionated by affinity chromatography on matrix-bound antithrombin iii and by gel filtration. , 1976, Thrombosis research.

[72]  F. Ofosu,et al.  Effects of Sulfated Polysaccharides on Inhibition of Thrombus Formation initiated by Different Stimuli , 1989, Thrombosis and Haemostasis.

[73]  F. Bonini,et al.  In vivo neutralization of low-molecular weight heparin fraction CY 216 by protamine. , 1985, Seminars in thrombosis and hemostasis.

[74]  V. Fuster,et al.  The pathogenesis of coronary artery disease and the acute coronary syndromes (2). , 1992, The New England journal of medicine.

[75]  U. Abildgaard.  Highly purified antithrombin 3 with heparin cofactor activity prepared by disc electrophoresis. , 1968, Scandinavian journal of clinical and laboratory investigation.

[76]  H. Hemker,et al.  The Mode of Action of Heparin in Plasma , 1988, Thrombosis and Haemostasis.

[77]  L. Jaques,et al.  Vascular sequestration of heparin. , 1978, Thrombosis research.

[78]  J. Fareed,et al.  STRUCTURAL STUDIES ON A BIOLOGICALLY ACTIVE HEXASACCHARIDE OBTAINED FROM HEPARIN , 1981, Annals of the New York Academy of Sciences.

[79]  E. Crowell,et al.  Randomized prospective trial of continuous vs intermittent heparin therapy. , 1976, JAMA.

[80]  G. Torri,et al.  The structure of heparin oligosaccharide fragments with high anti-(factor Xa) activity containing the minimal antithrombin III-binding sequence. Chemical and 13C nuclear-magnetic-resonance studies. , 1981, The Biochemical journal.

[81]  C. Patney.  Good-by, Mary. , 1970, Lancet.

[82]  J. Hsia,et al.  A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. Heparin-Aspirin Reperfusion Trial (HART) Investigators. , 1990, The New England journal of medicine.

[83]  W. Geerts,et al.  Prevention of Deep Vein Thrombosis after Major Knee Surgery - A Randomized, Double-Blind Trial Comparing a Low Molecular Weight Heparin Fragment (Enoxaparin) to Placebo , 1992, Thrombosis and Haemostasis.

[84]  D. Demis,et al.  Heparin Metabolism: Isolation and Characterization of Uroheparin , 1966, Nature.

[85]  J. Hirsh,et al.  A randomized trial of less intense postoperative warfarin or aspirin therapy in the prevention of venous thromboembolism after surgery for fractured hip. , 1989, Archives of internal medicine.

[86]  R. Rosenberg,et al.  Effect of heparin and heparin fractions on platelet aggregation. , 1980, The Journal of clinical investigation.

[87]  R. Collins,et al.  Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery. , 1988, The New England journal of medicine.

[88]  J. Wilson,et al.  Heparin therapy in venous thromboembolism. , 1981, The American journal of medicine.

[89]  B. Mulloy,et al.  The molecular-weight range of mucosal-heparin preparations. , 1976, Carbohydrate research.

[90]  C. Francis,et al.  Two-step warfarin therapy. Prevention of postoperative venous thrombosis without excessive bleeding. , 1983, JAMA.

[91]  A. Morabia.  HEPARIN DOSES AND MAJOR BLEEDINGS , 1986, The Lancet.

[92]  D. J. King,et al.  Heparin-associated thrombocytopenia. , 1984, Annals of internal medicine.

[93]  J. Hirsh,et al.  A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. , 1972, The New England journal of medicine.

[94]  D. Bergqvist,et al.  Effects of an Enzymatically Depolymerized Heparin as Compared with Conventional Heparin in Healthy Volunteers , 1987, Thrombosis and Haemostasis.

[95]  M. Nesheim.  A simple rate law that describes the kinetics of the heparin-catalyzed reaction between antithrombin III and thrombin. , 1983, The Journal of biological chemistry.

[96]  W. Rock,et al.  In vitro aggregation of normal platelets: a hypothetical first-approximation model for light extinction in platelet-rich plasma. , 1986, Haemostasis.

[97]  J. Hirsh,et al.  Hemorrhagic doses of heparin and other glycosaminoglycans induce a platelet defect. , 1986, Thrombosis research.

[98]  T. Mckenna,et al.  Routine heparin therapy inhibits adrenal aldosterone production. , 1983, The Journal of clinical endocrinology and metabolism.

[99]  G. Raskob,et al.  Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. , 1986, The New England journal of medicine.

[100]  P. White,et al.  Thrombotic Complications of Heparin Therapy Including Six Cases of Heparin‐Induced Skin Necrosis , 1979, Annals of surgery.

[101]  F. Fabris,et al.  Normal and low molecular weight heparins: interaction with human platelets , 1983, European journal of clinical investigation.

[102]  H. Braunsteiner,et al.  [Pathogenesis of thrombosis]. , 1950, Schweizerische medizinische Wochenschrift.

[103]  M. LeWinter,et al.  Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. , 1983, The New England journal of medicine.

[104]  J. Hirsh,et al.  The inhibition of thrombin-dependent positive-feedback reactions is critical to the expression of the anticoagulant effect of heparin. , 1987, The Biochemical journal.

[105]  J. Hirsh,et al.  Antithrombotic and bleeding effects of glycosaminoglycans with different degrees of sulphation , 1989, British journal of haematology.

[106]  J. Bonnet,et al.  [Intravenous thrombolysis in myocardial infarction. Influence of the quality of the anticoagulation on the early recurrence rate of angina or infarction]. , 1988, Archives des maladies du coeur et des vaisseaux.

[107]  T. Pang,et al.  Prevention of thromboembolism after spinal cord injury using low-molecular-weight heparin. , 1990, Annals of internal medicine.

[108]  M. Samama,et al.  The Antithrombotic Activity and Pharmacokinetics of Enoxaparine, A Low Molecular Weight Heparin, In Humans Given Single Subcutaneous Doses of 20 to 80 mg , 1988, Journal of clinical pharmacology.

[109]  M. Simoons,et al.  Correlation between level of heparinization and patency of the infarct-related coronary artery after treatment of acute myocardial infarction with alteplase (rt-PA). , 1992, Journal of the American College of Cardiology.

[110]  B. Modan,et al.  Reduction of mortality in general medical in-patients by low-dose heparin prophylaxis. , 1982, Annals of internal medicine.

[111]  E. Warner,et al.  THE INHIBITION OF BLOOD CLOTTING: AN UNIDENTIFIED SUBSTANCE WHICH ACTS IN CONJUNCTION WITH HEPARIN TO PREVENT THE CONVERSION OF PROTHROMBIN INTO THROMBIN , 1939 .

[112]  C. Mattsson,et al.  Pharmacokinetics of Heparin and Low Molecular Weight Heparin Fragment (Fragmin®) in Rabbits with Impaired Renal or Metabolic Clearance , 1987, Thrombosis and Haemostasis.

[113]  H. Büller,et al.  A randomized blind study comparing standard heparin and a new low molecular weight heparinoid in cardiopulmonary bypass surgery in dogs. , 1985, The Journal of laboratory and clinical medicine.

[114]  P. Constantinides,et al.  Plaque fissures in human coronary thrombosis , 1966 .

[115]  M. Hoylaerts,et al.  Heparin binding properties of human histidine-rich glycoprotein. Mechanism and role in the neutralization of heparin in plasma. , 1983, The Journal of biological chemistry.

[116]  D. Bergqvist,et al.  The effect of heparin fragments of different molecular weights on experimental thrombosis and haemostasis. , 1985, Thrombosis research.

[117]  T. van Dinther,et al.  ORG 10172: a low molecular weight heparinoid anticoagulant with a long half-life in man. , 1987, British journal of clinical pharmacology.

[118]  J. McLean.  THE THROMBOPLASTIC ACTION OF CEPHALIN , 1916 .

[119]  K. Tanaka.  [Thrombosis and fibrinolysis]. , 1969, Rinsho byori. The Japanese journal of clinical pathology.

[120]  D. Tollefsen,et al.  Heparin cofactor II. Purification and properties of a heparin-dependent inhibitor of thrombin in human plasma. , 1982, The Journal of biological chemistry.

[121]  S. Vallabhajosula,et al.  Dynamic monitoring of platelet deposition on severely damaged vessel wall in flowing blood. Effects of different stenoses on thrombus growth. , 1990, Arteriosclerosis.

[122]  U. Albrechtsson,et al.  NEED FOR LONG-TERM ANTICOAGULANT TREATMENT IN SYMPTOMATIC CALF-VEIN THROMBOSIS , 1985, The Lancet.

[123]  A. Gnasso,et al.  Inhibition of low molecular weight heparin by protamine chloride in vivo. , 1985, Thrombosis research.

[124]  J. Hirsh.  Heparin induced bleeding. , 1984, Nouvelle revue francaise d'hematologie.

[125]  C. O'connor,et al.  A randomized trial of intravenous heparin in conjunction with anistreplase (anisoylated plasminogen streptokinase activator complex) in acute myocardial infarction: the Duke University Clinical Cardiology Study (DUCCS) 1. , 1994, Journal of the American College of Cardiology.

[126]  J. Hirsh,et al.  A comparison of the antithrombotic and haemorrhagic effects of low molecular weight heparin fractions: the influence of the method of preparation. , 1984, Thrombosis research.

[127]  H. Yett,et al.  The hazards of aspirin plus heparin. , 1978, The New England journal of medicine.

[128]  J. Hirsh,et al.  Effects of heparin, its low molecular weight fractions and other glycosaminoglycans on thrombus growth in vivo. , 1985, Thrombosis research.

[129]  E. Bardana,et al.  Heparin sensitivity. Report of a case. , 1973, Archives of internal medicine.

[130]  B. Boneu,et al.  Pharmacokinetic Studies of Standard Unfractionated Heparin, and Low Molecular Weight Heparins in the Rabbit , 1988, Seminars in thrombosis and hemostasis.

[131]  M. Pfisterer,et al.  Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomised double blind European Cooperative Study Group trial. , 1992, British heart journal.

[132]  L. Jaques.  Heparins--anionic polyelectrolyte drugs. , 1979, Pharmacological reviews.

[133]  E. Marciniak.  Factor‐Xa Inactivation by Antithrombin III , 1973 .

[134]  E. Veys,et al.  HL-A AND INFECTIVE SACROILEITIS , 1974 .

[135]  M. Petitou,et al.  Structure-activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity. , 1983, Biochemical and biophysical research communications.

[136]  T. van Dinther,et al.  Safety and pharmacokinetics of the low molecular weight heparinoid Org 10172 administered to healthy elderly volunteers. , 1989, British journal of clinical pharmacology.

[137]  J. Hirsh,et al.  Establishing a Therapeutic Range for Heparin Therapy , 1993, Annals of Internal Medicine.

[138]  P. Brill-Edwards,et al.  Heparin Effect on Bone Density , 1990, Thrombosis and Haemostasis.

[139]  J. Hopwood,et al.  Anticoagulant activity of heparin: Separation of high‐activity and low‐activity heparin species by affinity chromatography on immobilized antithrombin , 1976, FEBS letters.

[140]  A. Planès,et al.  Prevention of Postoperative Venous Thrombosis: A Randomized Trial Comparing Unfractionated Heparin with Low Molecular Weight Heparin in Patients Undergoing Total Hip Replacement , 1988, Thrombosis and Haemostasis.

[141]  M. Walker,et al.  Subcutaneous calcium heparin versus intravenous sodium heparin in treatment of established acute deep vein thrombosis of the legs: a multicentre prospective randomised trial. , 1987, British medical journal.

[142]  P. Ockelford,et al.  A Double-Blind Randomized Placebo Controlled Trial of Thromboprophylaxis in Major Elective General Surgery Using Once Daily Injections of a Low Molecular Weight Heparin Fragment (Fragmin) , 1989, Thrombosis and Haemostasis.

[143]  Gruppo Italiano per lo Studio della Soprawivenza nell'Inf Miocardico..  MEDICAL SCIENCE GISSI-2: A factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12 490 patients with acute myocardial infarction , 1990, The Lancet.

[144]  K. Preissner,et al.  Neutralization and binding of heparin by S protein/vitronectin in the inhibition of factor Xa by antithrombin III. Involvement of an inducible heparin-binding domain of S protein/vitronectin. , 1987, The Journal of biological chemistry.

[145]  G. Coggi,et al.  Prophylaxis of fatal pulmonary embolism in general surgery using low-molecular weight heparin Cy 216: a multicentre, double-blind, randomized, controlled, clinical trial versus placebo (STEP). STEP-Study Group. , 1989, International surgery.

[146]  A. Gallus.  Overview of the Management of Thrombotic Disorders , 1989, Seminars in thrombosis and hemostasis.

[147]  J. Hirsh,et al.  Comparison of the in vivo hemorrhagic and antithrombotic effects of a low antithrombin-III affinity heparin fraction. , 1982, Thrombosis research.

[148]  P. Olsson,et al.  The elimination from plasma of intravenous heparin. An experimental study on dogs and humans. , 2009, Acta medica Scandinavica.

[149]  H R Büller,et al.  Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis. , 1992, The New England journal of medicine.

[150]  A. Linker,et al.  Structure of the antithrombin-binding site in heparin. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[151]  B. Glimelius,et al.  Binding of heparin on the surface of cultured human endothelial cells. , 1978, Thrombosis research.

[152]  J. Hirsh,et al.  DOUBLE-BLIND RANDOMISED TRIAL OF ORG 10172 LOW-MOLECULAR-WEIGHT HEPARINOID IN PREVENTION OF DEEP-VEIN THROMBOSIS IN THROMBOTIC STROKE , 1987, The Lancet.

[153]  P. Hogg,et al.  Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: implications for heparin efficacy. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[154]  C. Esmon,et al.  The effects of phospholipid and factor Va on the inhibition of factor Xa by antithrombin III. , 1979, Biochemical and biophysical research communications.

[155]  G M Oosta,et al.  The kinetics of hemostatic enzyme-antithrombin interactions in the presence of low molecular weight heparin. , 1980, The Journal of biological chemistry.

[156]  B. Fagher,et al.  Heparin treatment of deep vein thrombosis. Effects and complications after continuous or intermittent heparin administration. , 2009, Acta medica Scandinavica.

[157]  H. Büller,et al.  Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis , 1992, The Lancet.

[158]  S Shapiro,et al.  Efficacy and toxicity of heparin in relation to age and sex. , 1968, The New England journal of medicine.

[159]  C. Mattsson,et al.  Anticoagulant and antithrombotic effects of heparin and low molecular weight heparin fragments in rabbits. , 1982, Thrombosis research.

[160]  M. Petitou,et al.  Heparin degradation in the endothelial cells. , 1987, Thrombosis research.

[161]  J. Hirsh,et al.  Bleeding associated with antithrombotic therapy. , 1980, Seminars in hematology.

[162]  A. Clowes,et al.  Suppression by heparin of smooth muscle cell proliferation in injured arteries , 1977, Nature.

[163]  C. A. Simon,et al.  [Heparin treatment. Comparison between intravenous and subcutaneous administration]. , 1979, Schweizerische medizinische Wochenschrift.

[164]  C. Eika.  Inhibition of thrombin induced aggregation of human platelets by heparin. , 2009, Scandinavian journal of haematology.

[165]  M. Gent,et al.  A Low-Molecular-Weight Heparinoid Compared with Unfractionated Heparin in the Prevention of Deep Vein Thrombosis in Patients with Acute Ischemic Stroke , 1992, Annals of Internal Medicine.

[166]  Thomas E. Moritz,et al.  Implications of preoperative administration of aspirin in patients undergoing coronary artery bypass grafting. Department of Veterans Affairs Cooperative Study on Antiplatelet Therapy. , 1990, Journal of the American College of Cardiology.

[167]  E W Salzman,et al.  Management of heparin therapy: Controlled prospective trial. , 1975, The New England journal of medicine.

[168]  J. Fricker,et al.  Low dose heparin versus low molecular weight heparin (Kabi 2165, Fragmin®) in the prophylaxis of thromboembolic complications of abdominal oncological surgery , 1988, European journal of clinical investigation.

[169]  Use of anticoagulants during pregnancy. , 1989, Chest.

[170]  S. Soimakallio,et al.  Thromboprophylaxis in patients with hip fractures: a prospective, randomized, comparative study between Org 10172 and dextran 70. , 1991, Surgery.

[171]  D. Doyle,et al.  Comparison of high-dose with low-dose subcutaneous heparin to prevent left ventricular mural thrombosis in patients with acute transmural anterior myocardial infarction. , 1989, The New England journal of medicine.

[172]  D. W. Barritt,et al.  Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial. , 1960, Lancet.

[173]  J. Boissel,et al.  Prevention of perioperative deep vein thrombosis in general surgery: A multicentre double blind study comparing two doses of Logiparin and standard heparin , 1991, The British journal of surgery.

[174]  D. Heiden,et al.  Impairment by Heparin of Primary Haemostasis and Platelet [14C]5‐Hydroxytryptamine Release , 1977, British journal of haematology.

[175]  R. Rosenberg,et al.  Correlation between structure and function of heparin. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[176]  P. G. Bentley,et al.  An objective study of alternative methods of heparin administration. , 1980, Thrombosis Research.

[177]  M. Samama,et al.  Comparative pharmacokinetics of a low molecular weight heparin (PK 10 169) and unfractionated heparin after intravenous and subcutaneous administration. , 1985, Thrombosis research.

[178]  B. Ljungberg,et al.  Subcutaneous administration of heparin. A randomised comparison with intravenous administration of heparin to patients with deep-vein thrombosis. , 1982, Thrombosis research.

[179]  T. Wakefield,et al.  Protamine reversal of anticoagulation achieved with a low molecular weight heparin. The effects on eicosanoids, clotting and complement factors. , 1987, Thrombosis research.

[180]  D. Lane,et al.  Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4. , 1984, The Biochemical journal.

[181]  M. Parker,et al.  Role of heparin after intravenous thrombolytic therapy for acute myocardial infarction. , 1987, The American journal of cardiology.

[182]  R. Conroy,et al.  Heparin inhibition of von Willebrand factor-dependent platelet function in vitro and in vivo. , 1991, The Journal of clinical investigation.

[183]  Y. Friedman,et al.  Studies on the heparin sulphamidase activity from rat spleen. Intracellular distribution and characterization of the enzyme. , 1974, The Biochemical journal.

[184]  J. Hirsh,et al.  Prevention of deep vein thrombosis after elective hip surgery. A randomized trial comparing low molecular weight heparin with standard unfractionated heparin. , 1991, Annals of internal medicine.

[185]  Y. Gruel,et al.  Treatment of Heparin-Associated Thrombocytopenia and Thrombosis with Low Molecular Weight Heparin (CY 216) , 1985, Seminars in thrombosis and hemostasis.

[186]  D. Tate,et al.  Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction. , 1990, The American journal of cardiology.

[187]  G. Agnelli,et al.  The Comparative Effects of Recombinant Hirudin (CGP 39393) and Standard Heparin on Thrombus Growth in Rabbits , 1990, Thrombosis and Haemostasis.

[188]  M. Barbanti,et al.  Comparison of the antithrombotic and haemorrhagic effects of heparin and a new low molecular weight heparin in rats. , 1985, Haemostasis.

[189]  M. Mant,et al.  HÆMORRHAGIC COMPLICATIONS OF HEPARIN THERAPY , 1977, The Lancet.